Thus, the microbe driven IL-22 production [179,298] can untwine how antibiotic-related dysbiosis and cancer therapy may predispose to secondary fungal infections and suggests that therapies aimed at restoring the AhR/IL-22 axis at the mucosal surface could be of therapeutic benefit. The gene discussed is IL22; the disease is fungal infectious disease.